Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combining immunotherapy with radiation therapy in thoracic oncology.

Literature DB >> 30206494

Combining immunotherapy with radiation therapy in thoracic oncology.

Shahed N Badiyan¹, Michael C Roach², Michael D Chuong³, Stephanie R Rice¹, Nasarachi E Onyeuku¹, Jill Remick¹, Srinivas Chilukuri⁴, Erica Glass¹, Pranshu Mohindra¹, Charles B Simone¹.

Abstract

Thoracic malignancies comprise some of the most common and deadly cancers. Immunotherapies have been proven to improve survival outcomes for patients with advanced non-small cell lung cancer (NSCLC) and show great potential for patients with other thoracic malignancies. Radiation therapy (RT), an established and effective treatment for thoracic cancers, has acted synergistically with immunotherapies in preclinical studies. Ongoing clinical trials are exploring the clinical benefits of combining RT with immunotherapies and the optimal manner in which to deliver these complementary treatments.

Entities: Disease Species

Keywords: Radiation therapy (RT); esophageal cancer; immune checkpoint inhibitors (ICIs); immunotherapy; lung cancer; mesothelioma; thymoma

Year: 2018 PMID： 30206494 PMCID： PMC6123189 DOI： 10.21037/jtd.2018.05.73

Source DB: PubMed Journal: J Thorac Dis ISSN： 2072-1439 Impact factor: 2.895

119 in total

1. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

Authors: Luana Calabrò; Aldo Morra; Ester Fonsatti; Ornella Cutaia; Carolina Fazio; Diego Annesi; Marica Lenoci; Giovanni Amato; Riccardo Danielli; Maresa Altomonte; Diana Giannarelli; Anna Maria Di Giacomo; Michele Maio
Journal: Lancet Respir Med Date: 2015-03-26 Impact factor: 30.700

2. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma.

Authors: Tobias Weiss; Michael Weller; Matthias Guckenberger; Charles L Sentman; Patrick Roth
Journal: Cancer Res Date: 2017-12-08 Impact factor: 12.701

Review 3. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.

Authors: David R Spigel; Mark A Socinski
Journal: J Thorac Oncol Date: 2013-05 Impact factor: 15.609

Review 4. Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer.

Authors: Neil K Taunk; Andreas Rimner; Melissa Culligan; Joseph S Friedberg; Julie Brahmer; Jamie Chaft
Journal: Transl Lung Cancer Res Date: 2017-04

5. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

Authors: Everett E Vokes; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey Neill; James N Atkins; Dorothy M Watson; Wallace Akerley; Mark R Green
Journal: J Clin Oncol Date: 2007-04-02 Impact factor: 44.544

6. Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.

Authors: Daniel H Sterman; Evan Alley; James P Stevenson; Joseph Friedberg; Susan Metzger; Adri Recio; Edmund K Moon; Andrew R Haas; Anil Vachani; Sharyn I Katz; Jing Sun; Daniel F Heitjan; Wei-Ting Hwang; Leslie Litzky; Jennifer H Yearley; Kay See Tan; Emmanouil Papasavvas; Paul Kennedy; Luis J Montaner; Keith A Cengel; Charles B Simone; Melissa Culligan; Corey J Langer; Steven M Albelda
Journal: Clin Cancer Res Date: 2016-03-11 Impact factor: 12.531

7. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Authors: Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman
Journal: Cancer Immunol Res Date: 2013-04-07 Impact factor: 11.151

8. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors: Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal: N Engl J Med Date: 2015-09-27 Impact factor: 91.245

9. Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination.

Authors: Gaute Lund Hansen; Gustav Gaudernack; Paal Fredrik Brunsvig; Milada Cvancarova; Jon Amund Kyte
Journal: Cancer Immunol Immunother Date: 2015-10-26 Impact factor: 6.968

10. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors: Y Ishida; Y Agata; K Shibahara; T Honjo
Journal: EMBO J Date: 1992-11 Impact factor: 11.598

7 in total

1. Pneumonitis after Stereotactic Thoracic Radioimmunotherapy with Checkpoint Inhibitors: Exploration of the Dose-Volume-Effect Correlation.

Authors: Kim Melanie Kraus; Caroline Bauer; Benedikt Feuerecker; Julius Clemens Fischer; Kai Joachim Borm; Denise Bernhardt; Stephanie Elisabeth Combs
Journal: Cancers (Basel) Date: 2022-06-15 Impact factor: 6.575

Review 2. The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors.

Authors: Malek Kreidieh; Youssef H Zeidan; Ali Shamseddine
Journal: J Oncol Date: 2019-04-28 Impact factor: 4.375

3. A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model.

Authors: Yun Hu; Sébastien Paris; Hampartsoum Barsoumian; Chike O Abana; Kewen He; Duygu Sezen; Mark Wasley; Fatemeh Masrorpour; Dawei Chen; Liangpeng Yang; Joe D Dunn; Saumil Gandhi; Quynh-Nhu Nguyen; Maria Angelica Cortez; James W Welsh
Journal: J Nanobiotechnology Date: 2021-12-11 Impact factor: 10.435

4. A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada.

Authors: Anifat A Elegbede; Amanda J Gibson; Andrea S Fung; Winson Y Cheung; Michelle L Dean; D Gwyn Bebb; Aliyah Pabani
Journal: JTO Clin Res Rep Date: 2021-10-28